By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss drug Wegovy in the world's most populous nation, in a move that will challenge rival Eli Lilly's Mounjaro,

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes that its position as a market leader for insulin products in the country could give it an edge.

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.